Imaging Brain Injury in Multiple Sclerosis
Molecular Imaging of NET Using [C-11]MRB-PET in MS
Recruiting
Phase 1
Phase 2
Interventional Study
Multiple Sclerosis
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
Healthy Volunteers Welcome
You do not need to have the condition being studied to take part.
At a Glance
- Age
- 18 – 60
- Sex
- Any
- Trial phase
- Phase 1/2
- Study type
- Interventional
- Purpose
- Diagnostic
- Participants needed
- 19 (estimated)
- Sponsor
- Brigham and Women's Hospital · Other
Who this trial is looking for
This trial is looking for people with Multiple Sclerosis to understand brain injury better. Participants will undergo brain scans using a special imaging technique called PET and will answer questions about their health.
Are You a Good Fit for This Trial?
You may be able to join if
- I have been diagnosed with Multiple Sclerosis.
- I am between 18 and 70 years old.
- I am willing to undergo imaging tests.
- I can provide informed consent.
You may not be able to join if
- I have a severe psychiatric condition like schizophrenia.
- I have another known neurological disorder.
- I have a history of head injury.
- I abuse substances.
- I am taking tricyclic antidepressants or similar medications.
- I have medical conditions that would prevent me from participating.
- I am pregnant or nursing.
- I have claustrophobia.
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.
Check Your Eligibility
About This Trial
This study aims to use \[C-11\]MRB PET (positron emission tomography) imaging to look at brain injury in patients with Multiple Sclerosis (MS) and healthy individuals. The overarching hypothesis is that there is decreased radioligand binding to the norepinephrine transporter in multiple sclerosis, reflecting injury to the noradrenergic system and that it plays a role in disease pathogenesis, its c…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
1. Individuals meeting the definition for Multiple Sclerosis by the International Panel Criteria, with an Expanded Disability Status Scale (EDSS) less than 7.5
2. Male and female subjects age 18 to 70 years
3. Subjects willing to undergo PET and MRI imaging
4. Subjects willing a…
Contacts